Sonnet biotherapeutics announces a publication demonstrating safety and tolerability of son-1010 in healthy volunteers

Princeton, nj / accesswire / february 29, 2024 / sonnet biotherapeutics holdings, inc., (nasdaq:sonn) a clinical-stage company developing targeted immunotherapeutic drugs for cancer, announced today the publication of clinical data on son-1010 in frontiers in immunology. son-1010, sonnet's lead proprietary monofunctional compound, combines the company's fully-human albumin-binding (fhab) construct with single-chain interleukin 12 (il‑12).
SONN Ratings Summary
SONN Quant Ranking